12:11 PM
 | 
Jul 27, 2018
 |  BioCentury  |  Emerging Company Profile

Wound-up bacteria

Ilya delivers CXCL12 via engineered bacteria to speed wound healing

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing.

According to CEO Evelina Vågesjö, the standard of care to treat wounds involves cleaning the wound site and re-dressing the wound about every three days. For acute wounds, antibiotics may be added to prevent infection.

Strategies to stimulate wound healing include the application of recombinant growth factors that promote physiological functions such as angiogenesis or cell proliferation. However, some growth factor therapies need to be applied as frequently as every four hours due to the proteolytic nature of the wound environment, she said. In contrast, she expects Ilya’s product will need to be applied about once every three days.

Read the full 632 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >